Cancer drug discovery is an inefficient process, with more than 90% of newly-19 discovered therapies failing to gain regulatory approval. Patient-derived models of cancer offer a 20
Introduction 42
Despite spending billions of dollars on the preclinical development of new anti-cancer 43 drugs, fewer than 1 in 10 new therapies make it from the bench to the bedside and gain FDA 44 approval (1). These sobering statistics clearly demonstrate that the preclinical models and 45 paradigms currently being used to discover new cancer treatments require improvement. This 46 need for improvement is exemplified by the slow progress in finding new therapies for sarcoma. 47
Sarcomas are rare, but highly aggressive cancers that are prevalent in children and young adults. 48
While sarcomas make up less than 1% of adult solid tumors, they account for nearly 15% of 49 pediatric solid tumors(2). For patients who present with metastatic disease, the 5-year survival is 50 just 16% (3). Few new therapies have emerged in recent decades, underscoring the need for 51 creative new approaches in drug discovery. 52
One approach that has increasingly become a part of the discovery pipeline is the use of 53 patient-derived models of cancer, including low-passage cell lines and patient-derived xenografts 54 (PDXs). To create these patient-derived models, individual patient tumors are grown directly in 55 culture or in immunocompromised mice. Each type of patient-derived model has unique 56 advantages: For example, patient-derived cell lines enable large-scale drug screens to take place 57 quickly and at low cost. On the other hand, the use of PDXs reduces the selective bottleneck of 58 cell line generation and maintains the stromal components of the original tumor, which are 59 increasingly recognized as critical components of a tumor's relative therapeutic sensitivity(4, 5). 60
These patient-derived models are also being used to develop personalized treatments and guide 61 development of novel targeted agents (6, 7). One study in colorectal cancers showed a 62 correlation between transplanted xenograft tumors and clinical response to cytotoxic therapy (8). 63
Another pilot clinical trial of patients with advanced solid tumors received systemic cytotoxic 64 therapies based on in vivo validation in PDXs (9). This study showed that 11 out of 17 treatment 65 regimens identified in PDX were clinically efficacious (10). Drug screening in this study was 66 done in vivo rather than in vitro and used over 200 treatment regimens, including both targeted 67 and non-targeted agents (10). A similar study in advanced sarcoma patients with a variety of 68 histologic subtypes also yielded concordant results between PDX and patient responses, with 13 69 out of 16 patients showing a correlation between efficacy of the top drug identified through PDX 70 drug trials and clinical outcomes (11). Yet despite these exciting results, there remains a 71 disconnect between drug testing in mice and performance in human patients. 72
Another approach for cancer drug discovery that is rapidly gaining attention is the study 73 of pet dogs with spontaneously-occurring sarcomas and the inclusion of these patients in 74 therapeutic trials. Canine sarcomas are far more prevalent than their human counterparts, 75
representing approximately 15% of all canine malignancies (12) and rendering them an 76 underutilized "model" of human disease (13, 14) . Unlike mouse models -which often fail to 77 recapitulate key conditions of spontaneous human disease -dogs share an environment with 78 humans, have an intact immune system, and have nearly identical treatment options. While there 79 are some differences in the histopathologic grading of soft tissue sarcomas between humans and 80 dogs, a study using canine soft tissue sarcomas to compare pathologic diagnoses between 81 veterinary and medical pathologists showed that the majority of canine tumors were given 82 diagnoses congruent with the human counterpart (15). Coupled with patient-derived models and 83 precision medicine strategies, a cross-species approach could illuminate new therapeutic options 84 for sarcoma patients with greater fidelity than the traditional "cells, then mice, then humans" 85 pathway. Most importantly, because the lifespan of dogs is much shorter than that of humans, discoveries in canine clinical trials can be made more quickly in canine patients given the rapid 87 progression of their lives relative to humans. 88
In the present work, we report the development and testing of a personalized medicine 89 pipeline that combines patient-derived models, personalized genomics, and drug screening 90 strategies to identify new potential therapies for a young dog who presented with seven 91 synchronous, spontaneous leiomyosarcomas. Using this pipeline, we first developed an early 92 passaged cell line and PDX for our patient. Using high throughput drug screen on the cell line, 93 we identified proteasome inhibitors as a candidate therapy for this patient, then validated the 94 tumor response to proteasome inhibition in vivo using the patient's PDX, and finally treated the 95 patient's recurrent tumor in the clinic with the proteasome inhibitor, bortezomib. Our work 96 provides a generalizable framework for personalized medicine strategies and highlights key 97 challenges in the development of such approaches. 98 99
Materials and Methods 100
Generation of patient-derived xenograft models 101 Tumor samples were collected from a three-year-old male golden retriever following 102 surgical resection of the tumors at University of Illinois at Urbana-Champaign, College of 103 Veterinary Medicine (Urbana, IL, USA) with the informed consent of the owner. PDX models of 104 the patient's sarcoma were generated as described previously, and all in vivo mouse experiments 105 were performed in accordance with the animal guidelines and with the approval of the 106 Institutional Animal Care and Use committee (IACUC) at the Duke University Medical Center 107 (16). To develop PDXs, the tumor sample was washed in phosphate buffered saline (PBS), 108 dissected into small pieces (<2 mm), and injected into the flanks of 8-10-week-old JAX NOD.CB17-PrkdcSCID-J mice obtained from the Duke University Rodent Genetic and Breeding 110
Core. Tumors were passaged into successive mice once the tumor size reached between 500 to 111 1,500 mm 3 . Resected PDX tumors were homogenized in a PBS suspension and 150 ߤ l of PDX 112 tissue-PBS suspensions at 150 mg/ml concentration were injected subcutaneously into the right 113 flanks of the 8 weeks old JAX NOD.CB17-PrkdcSCID-J mice. To maintain integrity of the 114 PDX tumor, passages were limited to the 3rd generation. 115 116
Low-passage cell line generation and characterization 117
Low passage cell lines were generated from the patient's PDX during passage one of the 118 PDX as follows. PDX tumor was surgically removed with a sterile blade, washed in PBS, and 119 small pieces (< 2mm) of tumor tissue were mechanically homogenized and then suspended in 120 cell growth media and cultured in 12-well plates with DMEM + 10% FBS + 1% 121 Penicillin/Streptomycin. To isolate tumor cells, growing colonies of cells were isolated by 122 trypsinization using O rings and cultured in fresh 12-well plates. This process was repeated until 123 a colony of cells was established that resembled pure tumor cells in morphology. Contamination 124 of the PDX cell line with mouse fibroblasts was detected by polymerase chain reaction (PCR) 125 using canine-specific and mouse-specific primers. The following primers were used: canine 126 reverse (5'-GTA AAG GCT GCC TGA GGA TAA G-3'), canine forward (5'-GGT CCA GGG 127 AAG ATC AGA AAT G-3'), mouse reverse (5'-AGG TGT CAC CAG GAC AAA TG-3'), and 128 mouse forward (5'-CTG CTT CGA GCC ATA GAA CTA A-3') (17 intraperitoneal injections. When the tumor volumes reached 100-150 mm 3 , mice were randomized (n = 5 mice for each treatment group) and 1 mg/kg bortezomib and 25 mg/kg 155 alvespimycin intraperitoneal injections were initiated three times a week (18, 19) . Control tumors 156 were treated with 100ߤ݈ of 5% DMSO diluted in PBS. Tumor volumes were measured three 157 times a week using calipers, and (length x (width) 2 )/2 was used to calculate the tumor size. Mice 158 were sacrificed on day 18 or if the tumor volume reached 1,500 mm 3 . 159 and homogenized using a bead beater at 10,000 rpm. Protein concentration was determined via 199
Bradford assay and was normalized to 5,000 μ g of protein in 1.6 M of urea using 50 mM 200 ammonium bicarbonate. Samples were then reduced with 10 mM dithiothreitol for 45 minutes at 201 32°C and alkylated with 25 mM iodoacetamide for 45 minutes at room temperature. Trypsin was 202 added to a 1:25 ratio (enzyme to total protein) and allowed to proceed for 18 hours at 37°C. After 203 digestion, peptides were acidified to pH 2.5 with trifluoroacetic acid (TFA) and subjected to C18 204 SPE cleanup (Sep-Pak, 50 mg bed). 205 Applying a personalized medicine pipeline to an unusual case of leiomyosarcoma 258
We enrolled a three-year-old Golden Retriever (Teddy) for this study who presented to a 259 veterinary primary care hospital with six synchronous leiomyosarcomas that underwent 260 excisional biopsy (Figure 1) . Teddy was then referred to the Small Animal Oncology team at the 261 University of Illinois at Urbana-Champaign for treatment of a mass near the stifle. This tumor 262 was excised and scars of the resected tumors were excised. During clipping and preparation for 263 these surgeries, the treating surgeon noted two new masses in addition to previous surgical scars 264 that were also resected and also determined to be high grade leiomyosarcoma (Figure 1) . 265
Pathology reports from the time of tumor excision noted an "ulcerated, inflamed, highly cellular, 266 invasive mass composed of neoplastic spindyloid cells arranged in short interlacing streams and 267 bundles with many neutrophils throughout the neoplasm with clusters of lymphocytes and 268 plasma cells at the periphery", which was consistent with high grade leiomyosarcoma. Following surgery, Teddy was started on empirical treatment with toceranib, a multi-receptor tyrosine 270 kinase inhibitor and the only FDA-approved targeted cancer therapeutic for dogs, given the high 271 risk for recurrent disease. Figure 2D) . 285 286 High-throughput drug screens identify proteasome inhibitors as a potential candidate therapy 287
To identify potential candidate therapies to treat Teddy, we performed two high-288 throughput drug screens. First, we used a panel of 119 FDA-approved anti-cancer drugs. 289 Importantly, this screen identified multiple standard-of-care therapies for soft tissue sarcomas, 290 such as doxorubicin and danurubicin (Figure 2E) . Interestingly, however, in addition to 291 standard-of-care therapies, the drug screen also identified several novel candidate drugs, such as 292 proteasome inhibitors, HDAC inhibitors (i.e. romidepsin), and MEK inhibitors, as candidate 293 agents (Figure 2E) . Analysis of drug hits grouped by pathway revealed sensitivity to protein and 294 nucleic acid synthesis pathways, autophagy, topoisomerases, HDACs, and c-kit/BCR/ABL 295 ( Figure 2F) . 296
To further identify and validate additional novel therapeutic targets, we next performed a 297 second-high throughput drug screen, this time using a larger panel of 2,100 bioactive 298 compounds. The BioActives compound library (Selleckchem) contains a mixture of FDA-299 approved and non-FDA approved small molecules with confirmed bioactivity against known 300 protein or pathway targets. The Bioactives collection is structurally diverse and is designed to 301 target many key pathways regulating cellular processes including proliferation, apoptosis and 302 signal transduction. Using the targeted pathway annotation for each compound, we were able to 303 select targets and pathways for which multiple drugs had significant inhibitory effects. We 304 hypothesized that this strategy would increase the likelihood of identifying the candidate 305 targets/pathways for which a given tumor is most vulnerable. Our initial analysis of the screen 306 We further explored the potential therapeutic efficacy of top pathways by analyzing the 315 number of inhibitors for each pathway that had >50% cell growth inhibition. Notably, both the 316 HSP and proteasome pathways had multiple drugs with >50% inhibition (15/19 and 5/11, 317 respectively) (Figure 3D and E) . In the proteasome inhibitor class, 4/11 drugs conferred >90% 318 cell growth inhibition. Likewise, in the HSP inhibitor drug class, 13 out of 19 drugs caused >90 319 % cell growth inhibition (Figure 3D and E) . From these two drug classes, we selected 320 alvespimycin (HSP inhibitor) and bortezomib (proteasome inhibitor) for further study. Both of 321 these drugs have known toxicity profiles, with bortezomib being FDA approved for the treatment 322 of multiple myeloma. In vitro validation of alvespimycin and bortezomib showed sub-323 micromolar IC 50 values of 345 nM and 6nM, respectively (Figure 3D and E) . 324
325
In vivo validation of alvespimycin and bortezomib in PDX models of LMS-D48X 326
We next used the LMS-D48X PDX to assess whether the top candidate therapies we 327 identified in vitro would be therapeutically active in the patient's matched PDX in vivo. 328
Interestingly, while alvespimycin showed >95% growth inhibition in vitro, the PDX was 329 unresponsive to this HSP inhibitor, with no difference in growth rate between vehicle-treated and 330 alvespimycin-treated tumors (Figure 4A) . On the other hand, tumors treated with bortezomib 331 showed significant tumor growth inhibition, consistent with the in vitro drug screen (Figure 4B , 332 C). Animal weights in LMS-D48 PDX mice did not change significantly from the vehicle-treated 333 tumors in either of the drug treatment groups (Figure 4D) . 334 335 From bench to bedside: Applying preclinical modeling to clinical practice For any personalized medicine approach to be clinically useful, it must provide insight 337 into the patient's disease within the time scale of clinical decision making. With an aggressive 338 disease course and high likelihood for recurrence, Teddy presented a unique opportunity to 339 assess the ability of our personalized medicine pipeline to meet the clinical demand for rapidly 340 providing data on potential therapies to treating clinicians. Teddy presented at a six month follow 341 up visit with lesions in the mediastinal and right iliac lymph nodes, nasal mucosa, and local 342 recurrence in the right pelvic limb (Figure 1 and Supplementary Figure 1) . Using the in vitro 343 screening and in vivo validations data from our pipeline, a decision was made to treat the patient 344 with systemic bortezomib. The patient was treated with intravenous bortezomib infusions at 345 1.3mg/m 2 twice weekly for four weeks and also received local palliative radiation therapy to the 346 right pelvic limb to alleviate pain associated with the limb lesion. Measurements of the right 347 pelvic limb lesion showed an initial decrease in tumor size during the first three weeks of 348 treatment; however, tumor growth resumed by the sixth week of treatment (Figure 5A) . Our analysis of patient-derived models of cancer identified bortezomib as a promising 357 treatment for Teddy. Consistent with these preclinical observations, Teddy showed an initial 358 response to bortezomib in the first three weeks of treatment. However, this response was short lived and tumor growth resumed however, Teddy also developed rapid resistance to systemic 360 bortezomib by day 36 of treatment (Figure 5A) . Given the substantial differences in response 361 between tumor sites, we sought to better understand the underlying genetic landscape of the 362 patient's tumors and the relationship between these tumors and our patient-derived models. To 363 do this, we performed whole exome sequencing and phylogenetic reconstructions on 11 samples 364 from Teddy, including seven primary tumors, one recurrent tumor, one PDX and matched cell 365 line, and normal tissue. Phylogenetic analysis of the tumors and patient-derived models grouped 366 the PDX and cell line with the recurrent tumor with strong bootstrap support ( Figure 6A and 367 Supplementary Figure 2) . With the exception of the distance trees, the grouping of the PDX 368 and cell line with the recurrent tumor was consistent for all other methods of phylogenetic 369 inference, including DNA compatibility, maximum parsimony, and maximum likelihood ( Figure  370 6B). We also counted the number of shared somatic mutations across all samples and found the 371 greatest similarity between the PDX, cell line, the recurrent tumor, and tumor 1 ( Figure 6C) . 372
Together, these results suggest that the PDX and cell line most closely resemble the recurrent 373 tumor. All other tumor samples shared little genetic overlap (3% to 16%). Tumor 7 was 374 particularly distinct from the other tumors, sharing just 3.5% of somatic mutations with all other 375 tumors ( Figure 6C) . Analysis of unique and shared somatic mutations revealed that unique 376 mutations dominate the genetic landscape of each tumor (Figure 6D) . To further understand the underlying molecular mechanisms of sensitivity and resistance 381 to bortezomib for this patient, we performed mass spectrometry proteomics analysis of ubiquitin-382 tagged proteins in PDX tumors treated with vehicle or bortezomib. Since bortezomib is a 383 proteasome inhibitor, we analyzed proteins that were differentially ubiquitinated in the PDX 384 treated with bortezomib as compared to vehicle-treated tumors. We identified a total of 290 385 differentially ubiquitinated proteins in vehicle-vs. bortezomib-treated PDX tumors (adjusted p-386 value <0.05), 160 of which showed increased ubiquitination and 130 of which showed decreased 387 ubiquitination (Figure 7A) . Analysis of differentially ubiquitinated targets revealed enrichment 388 for myosins and HSPs as the proteins with the greatest increase in ubiquitination in bortezomib-389 treated tumors as compared to vehicle-treated tumors (Figure 7A and Supplementary File 1) . It 390 is worth noting that the top hits were unique to this PDX, as additional proteomics analysis of 391 bortezomib-treated osteosarcoma PDXs yielded a different suite of ubiquitinated proteins 392 (Altunel et al., in preparation). Pathway analysis of proteins with increased ubiquitination 393 revealed enrichments in pathways related to actin, contractile filament movement, and the 394 proteasome ( Figure 7B) and pathways related to proteins with decreased ubiquitination were 395 enriched for adherens junctions, focal adhesions, and extracellular vesicles (Figure 7C) . 396 We next cross-referenced the proteomics analysis with our whole exome sequencing data 397 to better understand the varied clinical response and rapid progression on bortezomib. We 398 identified 10 proteins that contained identical somatic mutations across multiple samples 399 predicted to alter protein function that were also differentially-ubiquitinated in the PDX and cell-400 line (Figure 7D) . Interestingly, two of these 10 proteins are involved in pathways relevant to 401 proteasome inhibition and HSPs, respectively (Figure 7E) . Defective In Cullin Neddylation 1 402 Domain Containing 1 (DCUN1D1) is part of an E3 ubiquitin ligase complex for neddylation, and 403 heat shock protein 70 kDa member 8 (HSPA8) is integral to the HSP70 pathway and cellular 404 protein quality control systems (33, 34) . Notably, the DCUN1D1 mutation was unique to the 405 PDX and cell line (Figure 7E ), suggesting the tumor from which this PDX was derived may 406 have harbored unique genetics that could contribute to increased bortezomib sensitivity. Overall, 407 the presence of somatic mutations affecting genes related to the proteasome and the heat shock 408 protein pathway may explain the sensitivity to small molecule inhibitors targeting these 409 pathways. The extensive heterogeneity in somatic mutations across multiple tumors and the 410 patient-derived models may also help explain the rapid progression of the patient treated with the 411 proteasome inhibitor, bortezomib. 412 413
Discussion 414
A comparative oncology approach enables rapid testing of a drug discovery pipeline in the clinic 415
Our canine leiomyosarcoma patient provided an invaluable opportunity to test, in real 416 time, a personalized approach to cancer therapy. To do this, we generated patient-derived cancer 417 models, both in vitro and in vivo, that helped identify novel therapeutic options, including 418 proteasome inhibitors and HSP inhibitors. After identifying bortezomib as a potential drug for 419 clinical application, we provided the preclinical data to the veterinary oncology team who 420 initiated personalized therapy with bortezomib for local recurrence and metastatic disease. 421
Though there was initial response to bortezomib in the setting of adjuvant palliative radiation 422 therapy for the local recurrence, additional metastatic sites showed either stable disease or 423 progression on bortezomib. While the outcome for this patient was only a slight delay in disease 424 progression, the entire process of evaluating a personalized therapy -from presentation to death 425 -was able to be carried out in approximately one year. 426
427
The impact of genetic heterogeneity on treatment response 428
There are a number of possibilities to explain the rapid progression on bortezomib for this 429 patient. One possible cause is the potential genetic drift that could be associated with generation 430 and passage of the PDX and cell line. Indeed, recent studies have shown that PDXs are subject to 431 mouse-specific selective pressures beyond a few passages (9). While we strive to keep our 432 passage numbers low for this reason, it is possible that even the first implantation of a tumor into 433 mice leads to selection of a specific sub-clone that has different properties from the original 434 tumor. Interestingly, phylogenetic reconstruction of all seven tumors, a recurrent tumor and the 435 PDX/cell line supports the grouping of the PDX/cell line with the recurrent tumor in a distinct 436 clade. Consistent with this grouping, a recurrent tumor, like the PDX and cell line, had an initial 437 response to bortezomib (Figure 5) . 438
One additional possibility for the rapid clinical progression on bortezomib could be that 439 there is not an established dosage or dosing schedule for treating canine cancer with bortezomib. 440
Bortezomib has been used in veterinary medicine as a therapy for golden retriever muscular 441 dystrophy and our therapeutic regimen was extrapolated from this (35). However, it is possible 442 our dosing regimen was incorrect in the context of leiomyosarcoma treatment. 443
A third possibility is that the recurrent and metastatic lesions acquired unique mutations 444
in key cellular pathways that conferred bortezomib resistance. Tumors are heterogeneous on the 445 individual level and within the population, greatly contributing to the challenge of discovering 446 novel universal drugs (37-39). Numerous studies across multiple cancer types have revealed 447 significant genotypic variability even within a single tumor (40, 41) (42-44). This is the case for 448 metastatic progression as well. For example, Wu et al. have shown that genetic signatures of 449 metastatic lesions are similar to each other, but distinct from primary tumors, suggesting key 450 genomic differences that could impact therapeutic response (45). 451
Driven by selective pressure from the tumor microenvironment , the inter-tumoral 452 heterogeneity exhibited by these tumors could explain the difference between the in vivo 453 response to bortezomib and the lack of response in the recurrent and metastatic lesions (46, 47) . 454
Consistent with this hypothesis, our analysis of whole exome sequencing data revealed 455 substantial tumor heterogeneity across the multiple tumors from this patient, as well as between 456 the group of samples including the recurrent tumor, PDX, and cell line. 457
It is possible that heterogeneity-mediated differences in response to therapy could be 458 addressed with combination targeted therapy or with therapies that target multiple oncogenic 459 pathways simultaneously (39, 48, 49) . Multiple studies in mouse models of EGFR mutant lung 460 cancer have shown the utility of combination therapies in overcoming treatment resistance (50-461 52). Our 2,100-compound drug screen identified multiple candidate drugs with both single 462 cellular targets and those that target multiple pathways. In future iterations of this personalized 463 pipeline, using combination therapy of top drugs identified from the drug screen could yield 464 promising results. 465 466 A multi-omics analysis identifies mechanisms of sensitivity and resistance to bortezomib 467
Using whole exome sequencing we were able to characterize the genomic differences 468 between the tumor used for preclinical modeling and the recurrent tumors treated with 469 bortezomib. In the context of multiple myeloma, for which bortezomib is a standard therapy, 470 multiple cellular pathways have been associated with bortezomib resistance, including mutations 471 in genes regulating the active site for bortezomib (53-56). Our proteomics analysis identified 472 pathways related to actin-myosin filaments, HSPs, and the proteasome as downregulated by 473 bortezomib (Figure 7 and Supplementary File 1) . The downregulation of skeletal myosins 474 (MYH1, MYH2, MYH4) by bortezomib is not easily explained, since skeletal myosins are 475 typically markers of rhabdomyosarcoma rather than leiomyosarcoma (58). However, inhibition 476 of pathways related to HSPs and the proteasome further validates the target specificity and 477 mechanism of action for bortezomib. Our integrated comparison of the ubiquitin proteomics data 478 with the exome sequencing data identified 10 key genes that were both differentially 479 ubiquitinated and mutated. Remarkably, two of these genes are members of the HSP and 480 proteasome pathways. This integrated multi-omics analysis suggests that mutations within these 481 two genes may explain, in part, the response to bortezomib. Likewise, the lack of mutation in 482 these two genes within other tumors in this patient may also explain the differential response to 483 bortezomib in different metastatic lesions of this patient. 
